Lee's Pharmaceuticals (00950): Subsidiary plans to acquire Alexza Pharmaceuticals, Inc.'s purchased assets related to Alexza's business for $15 million

Zhitong Financial App News, Lee's Pharmaceutical Company (00950) issued an announcement. On December 8, 2025 (after the transaction period), the buyer Nova Pneuma Incorporated (an indirect wholly-owned subsidiary of the Company), the company, the seller Alexza Pharmaceuticals, Inc. and the seller's parent company Grupo Ferrer International, S.A., entered into an asset purchase agreement. Based on this, the buyer agreed to acquire and the seller agreed to sell The cost of assets purchased in connection with Alexza's business was US$15 million.

The assets purchased include all assets, property, equipment and machinery, materials (including products), patents and other intellectual property rights, technical knowledge, rights and transferred contracts relating to Alexza's business.

The Group is mainly engaged in drug development, manufacturing and commercialization business in the Chinese and international markets. ^{The acquisition of the purchased assets is in line with the Group's strategy to expand its innovative drug delivery technology product portfolio (covering a wide range of indications) through the “Staccato®” platform, and is in line with the company's global expansion strategy. The acquisition of the assets purchased will bring value to the company and its shareholders. Investment highlights include: (a) “Staccato ®” One Breath Technology®, a proprietary platform technology with broad therapeutic potential; (b) complements and creates synergy effects with the company's existing product pipeline; (c) entering into a global licensing and manufacturing and supply agreement with UCB, a leading global biopharmaceutical company in the treatment of epilepsy, marking one of the company's global expansion strategies} An important milestone.